secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2022-09-14T23:59:59+00:00
Accession:  0001171843-22-006097
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst names Dr. Bill Sheridan CDO and Dr. Ryan Arnold CMO effective Sept 15, 2022
--------------------------------------------------------------------------------

- Dr. William Sheridan transitions from CMO to Chief Development Officer, focusing on pipeline advancement.
- Dr. Ryan Arnold promoted from SVP Global Medical Affairs (since March 2022) to Chief Medical Officer.
- Both join Dr. Helen Thackray (Chief R&D Officer) as physicians on leadership team.
- Dr. Sheridan joined BioCryst in 2008; Dr. Arnold has 20+ years industry experience including at Amgen, Genzyme, Biogen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184322006097/0001171843-22-006097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184322006097/f8k_091422.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-006097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer